Gabrielle R Kolakowski

This inventor holds 58 USPTO granted patents and 15 published patent applications, plus 13 CIPO patents and 17 EPO patents, primarily in RET Kinase Inhibitors (CPC class C07D). Top assignees: Array Biopharma Inc., Loxo Oncology, Inc., Eli Lilly and Company. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gabrielle R Kolakowski. Retrieved from https://idiyas.com/inventor/gabrielle-r-kolakowski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 58 (Patent Applications = 15)

% Patents Active = 86.2

CIPO Patents = 13 (Patent Applications = 10)

EPO Patents = 17 (Patent Applications = 27)

Average Co-Inventor Count = 8.7

ph-index = 11

Forward Citations = 379(Granted Patents)

Forward Citations (Not Self Cited) = 218(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Boulder, CO (US) (2015 - 2024)
Longmont, CO (US) (2021 - 2024)
Durango, CO (US) (2024)
Indianapolis, IN (US) (2024)

Company Filing History:

Eli Lilly and Company

patents

4. 3 out of 4

Petra Pharma Corporation

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

Areas of Expertise:

RET Kinase

PI3K

Inhibitors

Substituted Pyrazolo

Phosphoinositide

Macrocyclic Compounds

TRK Kinase

Point Mutations

Crystalline Forms

Bicyclic Urea

Pyrrolidinyl Urea

Cancer Treatment

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

2. 11970485 - RET kinase inhibitors (2024-04-30),

3. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),

4. 11964968 - Compounds useful for inhibiting RET kinase (2024-04-23),

5. 11878970 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2024-01-23),

6. 11873295 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2024-01-16),

7. 11851434 - Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors (2023-12-26),

8. 11807651 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2023-11-07),

9. 11697647 - RET kinase inhibitors (2023-07-11),

10. 11649227 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2023-05-16),

11. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

12. 11613533 - Compounds useful for inhibiting RET kinase (2023-03-28),

13. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),

14. 11524963 - Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors (2022-12-13),

15. 11472802 - Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors (2022-10-18),

Title: Gabrielle R Kolakowski: A Pioneer in RET Kinase Inhibition

Introduction: Gabrielle R Kolakowski is an innovative inventor based in Boulder, CO, known for his substantial contributions to medicinal chemistry and biotechnology. With an impressive portfolio of 58 patents, Kolakowski has made significant strides in developing therapies targeting RET kinases, which are crucial in treating various cancers and diseases.

Latest Patents: Among his latest innovations, Kolakowski has developed substituted pyrazolo[1,5-a]pyridine compounds that act as RET kinase inhibitors. These compounds, including their stereoisomers and pharmaceutically acceptable salts or solvates, have shown potential in treating RET-associated diseases and disorders. He has also disclosed formulations containing these compounds and methods for their synthesis, emphasizing their utility in combating RET-associated cancers.

Career Highlights: Kolakowski has honed his expertise while working at notable companies within the biotechnology sector, including Array Biopharma Inc. and Loxo Oncology, Inc. His inventive work has not only advanced scientific knowledge but has also contributed to the development of effective therapeutic solutions.

Collaborations: Throughout his career, Kolakowski has collaborated with esteemed colleagues, including Steven Wade Andrews and Yutong Jiang. These partnerships have fostered a creative environment for innovation and led to several advancements in the field.

Conclusion: Gabrielle R Kolakowski's dedication to research and innovation has placed him at the forefront of advancements in RET kinase inhibition. His extensive patent portfolio and collaborative efforts demonstrate his commitment to developing effective treatments for serious health conditions, solidifying his reputation as a leading figure in the pharmaceutical industry.

Profile summary based on public USPTO records.